{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T07:50:57Z","timestamp":1758959457759},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.ygyno.2009.02.022","type":"journal-article","created":{"date-parts":[[2009,6,5]],"date-time":"2009-06-05T09:21:14Z","timestamp":1244193674000},"page":"246-252","source":"Crossref","is-referenced-by-count":13,"title":["Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer"],"prefix":"10.1016","volume":"114","author":[{"given":"Amer K.","family":"Karam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing Wang","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewina","family":"Fung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Nossov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth Y.","family":"Karlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ygyno.2009.02.022_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.ygyno.2009.02.022_bib2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3747\/co.2007.148","article-title":"Optimal chemotherapy treatment for women with recurrent ovarian cancer","volume":"14","author":"Fung-Kee-Fung","year":"2007","journal-title":"Curr. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2009.02.022_bib3","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1994.12.9.1748","article-title":"Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study","volume":"12","author":"Thigpen","year":"1994","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2009.02.022_bib4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0090-8258(90)90174-J","article-title":"Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds","volume":"36","author":"Gore","year":"1990","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2009.02.022_bib5","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ygyno.2004.01.035","article-title":"Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer","volume":"93","author":"Markman","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"17","key":"10.1016\/j.ygyno.2009.02.022_bib6","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1200\/JCO.2004.05.065","article-title":"American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays","volume":"22","author":"Schrag","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2009.02.022_bib7","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/jnci\/82.7.582","article-title":"Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures","volume":"82","author":"Kern","year":"1990","journal-title":"J. Natl. Cancer Inst."},{"issue":"29","key":"10.1016\/j.ygyno.2009.02.022_bib8","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1200\/JCO.2005.03.2060","article-title":"Chemosensitivity and chemoresistance testing","volume":"23","author":"Markman","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.ygyno.2009.02.022_bib9","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2004.04.077","article-title":"Chemotherapy sensitivity and resistance assays: a systematic review","volume":"22","author":"Samson","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"11 Pt 1","key":"10.1016\/j.ygyno.2009.02.022_bib10","first-page":"5436","article-title":"Development of a miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumors","volume":"45","author":"Kern","year":"1985","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.ygyno.2009.02.022_bib11","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2009.02.022_bib12","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/cncr.22447","article-title":"Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome","volume":"109","author":"Salani","year":"2007","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.ygyno.2009.02.022_bib13","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"25","author":"Winter","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2009.02.022_bib14","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.1993.11.3.434","article-title":"Secondary cytoreduction for ovarian cancer following cisplatin therapy","volume":"11","author":"Segna","year":"1993","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2009.02.022_bib15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ygyno.2004.09.018","article-title":"Critical evaluation of secondary cytoreduction in recurrent ovarian cancer","volume":"95","author":"Munkarah","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2009.02.022_bib16","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.0.CO;2-X","article-title":"The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma","volume":"88","author":"Eisenkop","year":"2000","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2009.02.022_bib17","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/(SICI)1096-9098(200003)73:3<148::AID-JSO7>3.0.CO;2-U","article-title":"Extreme drug resistance assay and response to chemotherapy in patients with primary peritoneal carcinoma","volume":"73","author":"Eltabbakh","year":"2000","journal-title":"J. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2009.02.022_bib18","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1006\/gyno.1998.5109","article-title":"Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer","volume":"70","author":"Eltabbakh","year":"1998","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2009.02.022_bib19","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1067\/S0002-9378(03)00629-X","article-title":"Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy","volume":"189","author":"Loizzi","year":"2003","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.ygyno.2009.02.022_bib20","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1245\/s10434-006-9273-8","article-title":"Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer","volume":"14","author":"Benedetti Panici","year":"2007","journal-title":"Ann. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2009.02.022_bib21","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ygyno.2006.10.020","article-title":"Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer","volume":"104","author":"Santillan","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2009.02.022_bib22","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ygyno.2007.04.006","article-title":"Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma","volume":"106","author":"Tebes","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.02.022_bib23","series-title":"Cancer, principles and practice of oncology","author":"DeVita","year":"2001"},{"issue":"3","key":"10.1016\/j.ygyno.2009.02.022_bib24","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ygyno.2007.05.002","article-title":"Extreme drug resistance is common after prior exposure to paclitaxel","volume":"106","author":"Geisler","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2009.02.022_bib25","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ygyno.2008.05.019","article-title":"Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays","volume":"110","author":"McAlpine","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2009.02.022_bib26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1200\/JCO.1997.15.1.177","article-title":"Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study","volume":"15","author":"O'Reilly","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2009.02.022_bib27","first-page":"741","article-title":"Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing","volume":"3","author":"Cortazar","year":"1997","journal-title":"Clin. Cancer Res."},{"issue":"21","key":"10.1016\/j.ygyno.2009.02.022_bib28","first-page":"5181","article-title":"Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing","volume":"53","author":"Shaw","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2009.02.022_bib29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jcb.240630513","article-title":"Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer","volume":"24","author":"Shaw","year":"1996","journal-title":"J. Cell. Biochem., Suppl."},{"issue":"10","key":"10.1016\/j.ygyno.2009.02.022_bib30","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1158\/1078-0432.CCR-04-2398","article-title":"Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers","volume":"11","author":"Berchuck","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"31","key":"10.1016\/j.ygyno.2009.02.022_bib31","doi-asserted-by":"crossref","first-page":"7911","DOI":"10.1200\/JCO.2005.02.9363","article-title":"Unique gene expression profile based on pathologic response in epithelial ovarian cancer","volume":"23","author":"Spentzos","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.ygyno.2009.02.022_bib32","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1200\/JCO.2004.04.070","article-title":"Gene expression signature with independent prognostic significance in epithelial ovarian cancer","volume":"22","author":"Spentzos","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"9381","key":"10.1016\/j.ygyno.2009.02.022_bib33","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0140-6736(03)14023-8","article-title":"Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer","volume":"362","author":"Chang","year":"2003","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.ygyno.2009.02.022_bib34","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2009.02.022_bib35","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1006\/gyno.1995.1145","article-title":"The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial","volume":"57","author":"Maenpaa","year":"1995","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2009.02.022_bib36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00001813-199801000-00006","article-title":"Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer","volume":"9","author":"Kurbacher","year":"1998","journal-title":"Anticancer Drugsl"},{"issue":"9","key":"10.1016\/j.ygyno.2009.02.022_bib37","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/CAD.0b013e3281de727e","article-title":"A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer","volume":"18","author":"Cree","year":"2007","journal-title":"Anticancer Drugs"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082580900136X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082580900136X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T17:00:44Z","timestamp":1558371644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082580900136X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S009082580900136X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2009.02.022","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}